- Aditxt (NASDAQ:ADTX) and Evofem Biosciences (OTCQB:EVFM) on Monday stated that they’ve entered into the Second Amendment to the Amended and Restated Agreement and Plan of Merger beneath which Aditxt intends to amass Evofem.
- Under the Second Amendment, the events have prolonged the dates by which Aditxt shall full the remaining $3 million in funding to Evofem by the acquisition of three,000 shares of Evofem’s F-1 Preferred Stock.
- Aditxt will present $1.5 million of financing by September 30, 2024, and a further $1.5 million by October 31, 2024.
- Both firms proceed to work collaboratively to align strategic priorities and anticipate to shut the transaction within the fourth quarter of 2024.
- EVFM +3.09% premarket to $0.01.
- Source: Press Release
More on Aditx Therapeutics, Evofem Biosciences, and many others.
Source: Seekingalpha
